Sandra Prior, PhD joined NIBSC (UK) in 2015 working on the development of bioassay standards for therapeutic Monoclonal Antibodies (mAbs) and the investigation of structure-function in relation to the safety and efficacy of mAbs products. Member of EDQM mAb expert working party. She has over 15 years’ experience in applied immunology initially working in the field of vaccines (NIBSC, UK) and later in bioassay development and immunogenicity assessment of biotherapeutics in Lonza Biologics (Cambridge, UK).